Cargando…
First-line Advanced Cutaneous Melanoma Treatments: Where Do We Stand?
Cutaneous melanoma has always been a dreaded diagnosis because of its high mortality rate and its proclivity for invasiveness and metastasis. Historically, advanced melanoma treatment has been limited to chemotherapy and nonspecific immunotherapy agents that display poor curative potential and high...
Autores principales: | Abdulkarim, Louay S, Motley, Richard J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JMIR Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717133/ https://www.ncbi.nlm.nih.gov/pubmed/34914610 http://dx.doi.org/10.2196/29912 |
Ejemplares similares
-
Translational perspectives to treat Epidermolysis bullosa—Where do we stand?
por: Prodinger, Christine, et al.
Publicado: (2020) -
Equity and Quality of Health-care Access: Where Do We Stand and the Way Forward?
por: Banerjee, Amitav
Publicado: (2020) -
Current Melanoma Treatments: Where Do We Stand?
por: Moreira, Alvaro, et al.
Publicado: (2021) -
Cutaneous and Mucosal Melanomas of Uncommon Sites: Where Do We Stand Now?
por: Dika, Emi, et al.
Publicado: (2021) -
A decade of metaproteomics: Where we stand and what the future holds
por: Wilmes, Paul, et al.
Publicado: (2015)